(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.8%.
Aldeyra Therapeutics's earnings in 2026 is -$23,052,740.On average, 7 Wall Street analysts forecast ALDX's earnings for 2026 to be -$20,921,203, with the lowest ALDX earnings forecast at -$23,056,758, and the highest ALDX earnings forecast at -$19,636,250. On average, 7 Wall Street analysts forecast ALDX's earnings for 2027 to be -$17,108,573, with the lowest ALDX earnings forecast at -$23,647,957, and the highest ALDX earnings forecast at -$10,134,839.
In 2028, ALDX is forecast to generate -$8,922,278 in earnings, with the lowest earnings forecast at -$15,962,371 and the highest earnings forecast at -$1,266,855.